Tennessee is currently home to 1991 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 2a Study of DaxibotulinumtoxinA-lanm for Injection in Dynamic Forehead Lines and Glabellar Lines
Recruiting
This is a Phase 2a open-label, single-arm study to evaluate the effects of DaxibotulinumtoxinA-lanm (DAXI) for Injection on the treatment of dynamic forehead lines (FHL) and glabellar lines (GL). Approximately 40 subjects (18 years of age and above) with moderate to severe GL and FHL (all assessed at maximum contraction) will be screened for eligibility with the goal of enrolling and treating 30 subjects to receive DAXI for injection after providing informed consent. The primary objective of t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Revance, Nashville, Tennessee
Conditions: Glabellar Frown Lines
Prospective Clinical Assessment Study in Children With Hypochondroplasia
Recruiting
This is a long-term, multicenter, non-interventional study of children ages 2.5 to <17 years with hypochondroplasia (HCH).
Gender:
All
Ages:
Between 30 months and 16 years
Trial Updated:
05/21/2024
Locations: QED Investigative Site, Nashville, Tennessee
Conditions: Hypochondroplasia
Evaluation of the Clinical Performance of Daily Disposable Silicone Hydrogel Multifocal Toric Contact Lenses
Recruiting
This will be an open-label, 3-visit, single-arm, dispensing clinical trial to evaluate visual acuity.
Gender:
All
Ages:
Between 40 years and 70 years
Trial Updated:
05/21/2024
Locations: Optometry Group, LLC, Memphis, Tennessee
Conditions: Visual Acuity
Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with hypertriglyceridemia (HTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo and be evaluated for efficacy and safety.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Cardiovascular Research Center of Knoxville, Powell, Tennessee
Conditions: Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
Recruiting
This Phase 3 study will evaluate the safety and efficacy of plozasiran injection (ARO-APOC3) in adult participants with severe hypertriglyceridemia (SHTG). After providing informed consent eligible participants will be randomized to receive 4 doses (once every 3 months) of plozasiran or placebo, and be evaluated for efficacy and safety. After month 12, eligible participants will be offered an opportunity to continue in an optional open-label extension under a separate protocol.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Cardiovascular Research Center of Knoxville, Powell, Tennessee
Conditions: Severe Hypertriglyceridemia
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Recruiting
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Urology Associates, Nashville, Tennessee
Conditions: Non-Muscle Invasive Bladder Cancer
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Recruiting
The primary purpose of this study is to measure the efficacy and safety of efgartigimod intravenously (IV) compared to placebo in participants with Acetylcholine Receptor Binding Antibody (AChR-Ab) seronegative Generalized Myasthenia Gravis (gMG). Other objectives are to assess long-term efficacy, safety, and tolerability of efgartigimod. Study will consist of: Screening Part A: participants will be randomized to receive either efgartigimod IV or placebo Part B: participants completing part A... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Erlanger Neuroscience Institute, Chattanooga, Tennessee
Conditions: Generalized Myasthenia Gravis
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Recruiting
This phase III trial tests how well adding dinutuximab to induction chemotherapy along with standard of care surgery radiation and stem cell transplantation works for treating children with newly diagnosed high risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found in greater than normal amounts on some types of cancer cells. This helps cells of the immune system kill the cancer cells. Chemotherapy drugs such as cyclophosphamide, topotecan, c... Read More
Gender:
All
Ages:
30 years and below
Trial Updated:
05/21/2024
Locations: Saint Jude Children's Research Hospital, Memphis, Tennessee
Conditions: Ganglioneuroblastoma, Neuroblastoma
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Recruiting
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D[s]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: Sarah Cannon Cancer Institute, Nashville, Tennessee
Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Recruiting
The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agent (NHA). The primary study hypotheses are that opevesostat is superior to alternative abiraterone acetate or enzalutamide with respect to radiographic progression free survival (rPFS) per P... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: The West Clinic, PLLC dba West Cancer Center ( Site 0063), Germantown, Tennessee
Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Recruiting
The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of Physician's Choice (TPC) with respect to progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR), and overall survival (OS). The primary hypotheses are that sacituzumab tirumotecan is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and that sacituzumab tirumotecan is superior to TPC wit... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/21/2024
Locations: The West Clinic, PLLC dba West Cancer Center ( Site 4102), Germantown, Tennessee
Conditions: Endometrial Cancer
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Intravenous Secukinumab in Patients With GCA or PMR
Recruiting
This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tolerable after multiple doses of i.v. Secukinumab infusion in adult patients with giant cell arteritis (GCA) or polymyalgia rheumatica (PMR).
Gender:
All
Ages:
50 years and above
Trial Updated:
05/21/2024
Locations: West Tennessee Research Institute, Jackson, Tennessee
Conditions: Giant Cell Arteritis, Polymyalgia Rheumatica